Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Personalized Diabetes Medicine Program, |
RCV001174380 | SCV001337518 | likely benign | Monogenic diabetes | 2017-12-01 | criteria provided, single submitter | research | ACMG criteria: PP3 (5 predictors), BP4 (6 predictors), BP5 (alternate cause) = likely benign |
Ambry Genetics | RCV002558768 | SCV003613725 | uncertain significance | Inborn genetic diseases | 2022-04-13 | criteria provided, single submitter | clinical testing | The c.1276G>A (p.V426I) alteration is located in exon 5 (coding exon 5) of the SLC19A2 gene. This alteration results from a G to A substitution at nucleotide position 1276, causing the valine (V) at amino acid position 426 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |